Full US approval of Gilead’s Tecartus was the only positive decision last month.
ApexOnco Front Page
Recent articles
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA mutants, as well as wild types.
Studies presented at ASH show this to be true only up to a point.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Pfizer reveals the discontinuation of PF-08046044.
The company might have blown Enliven out of the water.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
